Overview

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Aspirin
Rivaroxaban